Page last updated: 2024-09-05

erlotinib hydrochloride and Lymphoma

erlotinib hydrochloride has been researched along with Lymphoma in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH	1
Bradbury, PA; Chan, KK; Chen, BE; Cheung, M; Cheung, WY; Ding, K; Hay, AE; Kornelsen, EA; Leighl, NB; Mittmann, N; Ng, RCH; Pater, JL; Tu, D	1
de Castro, J; García-Campelo, R; Isla, D; Provencio, M	1
Bendapudi, PK; Chen, J; Choi, P; Felsher, DW; Horng, G; Hughes, NP; Kawashima, T; Kitamura, T; Koh, S; Lin, HJ; Miller, VA; Paik, D; Schwartz, LH; Tran, PT	1

Reviews

1 review(s) available for erlotinib hydrochloride and Lymphoma

Article	Year
Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:7 Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphoma; Male; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome	2009

Article

Year

Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:7

Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphoma; Male; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome

2009

Trials

1 trial(s) available for erlotinib hydrochloride and Lymphoma

Article	Year
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer chemotherapy and pharmacology, 2021, Volume: 87, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib	2021

Article

Year

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.

Cancer chemotherapy and pharmacology, 2021, Volume: 87, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib

2021

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Lymphoma

Article	Year
The economic impact of the transition from branded to generic oncology drugs. Current oncology (Toronto, Ont.), 2019, Volume: 26, Issue:2 Topics: Antineoplastic Agents; Cetuximab; Cisplatin; Cost-Benefit Analysis; Cytarabine; Deoxycytidine; Dexamethasone; Drug Costs; Drugs, Generic; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphoma; Randomized Controlled Trials as Topic; Vinorelbine	2019
Survival and death signals can predict tumor response to therapy after oncogene inactivation. Science translational medicine, 2011, Oct-05, Volume: 3, Issue:103 Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Computer Simulation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Lymphoma; Mice; Mice, Transgenic; Models, Theoretical; Oncogenes; Polymerase Chain Reaction; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Quinazolines; Tumor Cells, Cultured	2011

Article

Year

The economic impact of the transition from branded to generic oncology drugs.

Current oncology (Toronto, Ont.), 2019, Volume: 26, Issue:2

Topics: Antineoplastic Agents; Cetuximab; Cisplatin; Cost-Benefit Analysis; Cytarabine; Deoxycytidine; Dexamethasone; Drug Costs; Drugs, Generic; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphoma; Randomized Controlled Trials as Topic; Vinorelbine

2019

Survival and death signals can predict tumor response to therapy after oncogene inactivation.

Science translational medicine, 2011, Oct-05, Volume: 3, Issue:103

Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Computer Simulation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Lymphoma; Mice; Mice, Transgenic; Models, Theoretical; Oncogenes; Polymerase Chain Reaction; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Quinazolines; Tumor Cells, Cultured

2011